Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer and Board Member. Huerga ...

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for ...

The tech industry has been so excited about generative AI that everyone seems to miss a fundamental point: it’s not at all ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

Nancy Pelosi's newest stock bet, Tempus AI, remains an enticing buy following a promising Q1 2025 earnings report.

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

The firm's Genomics revenues increased 89 percent, while Data and Services revenues rose 43 percent year over year.

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter of 2025, with year-over-year revenue ...